{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T13:02:01Z","timestamp":1781182921801,"version":"3.54.1"},"reference-count":19,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"unspecified","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Novartis Pharma AG","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Ophth"],"accepted":{"date-parts":[[2026,5,26]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Extending the dosing interval with the anti-vascular endothelial growth factor (VEGF) brolucizumab in the loading phase may reduce treatment burden while maintaining functional and anatomical outcomes for patients with neovascular age-related macular degeneration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We integrated population pharmacokinetic\/pharmacodynamic (PK\/PD) and quantitative system pharmacology (QSP) modelling approaches to evaluate the effect of brolucizumab 6\u2009mg on central subfield thickness (CSFT) and best-corrected visual acuity (BCVA) using an alternative reduced loading regimen (two or three administrations every 6 weeks (q6w)) followed by individualised every 12 weeks\/every 8 weeks (q12w\/q8w) maintenance. The simulation results were compared with the CSFT and BCVA outcomes in the phase 3 HAWK and HARRIER studies, in which patients received the approved loading regimen of 3 monthly doses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>For both loading regimens, simulations of the QSP model showed almost complete VEGF inhibition during the loading phase and free VEGF recovery commenced 6\u20127 weeks following the last loading dose, returning to baseline levels after 12\u201213 weeks.<\/jats:p>\n                    <jats:p>The population PK\/PD simulations showed that week 48 and week 36\u201348 mean BCVA and CSFT changes from baseline using the alternative loading regimen and individualised maintenance treatment were similar to\u2009HAWK and HARRIER study measures. Simulated disease activity assessments indicate that only 20% of patients needed third q6w loading dose before switching to q12w\/q8w maintenance treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This integrated modelling approach predicted that reducing the loading regimen of brolucizumab 6\u2009mg treatment to two or three doses every 6\u2009weeks is expected to result in similar efficacy outcomes, resulting in regulatory approval of this alternative dosing regimen in several countries.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjophth-2025-002660","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T12:40:18Z","timestamp":1781181618000},"page":"e002660","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Alternative posology for brolucizumab: a 6-week loading regimen is as effective as a 4-week regimen for the treatment of nAMD"],"prefix":"10.1136","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7485-1236","authenticated-orcid":false,"given":"Zufar","family":"Mulyukov","sequence":"first","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ufuk","family":"Olgac","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7261-5096","authenticated-orcid":false,"given":"Jeffrey D","family":"Kearns","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research Inc, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Pigeolet","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georges","family":"Weissgerber","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"2026061105401315000_11.2.e002660.1","doi-asserted-by":"crossref","first-page":"4317","DOI":"10.2147\/OPTH.S325763","article-title":"Importance of Treatment Duration: Unmasking Barriers and Discovering the Reasons for Undertreatment of Anti-VEGF Agents in Neovascular Age-Related Macular Degeneration","volume":"15","author":"Sobolewska","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"2026061105401315000_11.2.e002660.2","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-06362-w","article-title":"A model to quantify the influence of treatment patterns and optimize outcomes in nAMD","volume":"12","author":"Ziemssen","year":"2022","journal-title":"Sci Rep"},{"key":"2026061105401315000_11.2.e002660.3","first-page":"786870","article-title":"Anti-VEGF Treatment Strategies for Wet AMD","volume":"2012","author":"Kovach","year":"2012","journal-title":"J Ophthalmol"},{"key":"2026061105401315000_11.2.e002660.4","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1038\/s41433-023-02439-6","article-title":"Treat-and-extend dosing of intravitreal anti-VEGF agents in neovascular age-related macular degeneration: a meta-analysis","volume":"37","author":"Nichani","year":"2023","journal-title":"Eye (Lond)"},{"key":"2026061105401315000_11.2.e002660.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"2026061105401315000_11.2.e002660.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.06.028"},{"key":"2026061105401315000_11.2.e002660.7","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","article-title":"KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema","volume":"238","author":"Brown","year":"2022","journal-title":"Am J Ophthalmol"},{"key":"2026061105401315000_11.2.e002660.8","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajo.2023.07.012","article-title":"KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema","volume":"260","author":"Wykoff","year":"2024","journal-title":"Am J Ophthalmol"},{"key":"2026061105401315000_11.2.e002660.9","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1363"},{"key":"2026061105401315000_11.2.e002660.10","unstructured":"Beovu summary of product characteristics. Available: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/beovu-epar-product-information_en.pdf"},{"key":"2026061105401315000_11.2.e002660.11","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","article-title":"Single-Chain Antibody Fragment VEGF Inhibitor RTH258 for Neovascular Age-Related Macular Degeneration: A Randomized Controlled Study","volume":"123","author":"Holz","year":"2016","journal-title":"Ophthalmology"},{"key":"2026061105401315000_11.2.e002660.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.03.057"},{"key":"2026061105401315000_11.2.e002660.13","doi-asserted-by":"crossref","unstructured":"Kearns JD , Wassmann P , Olgac U , et al . A root cause analysis to identify the mechanistic drivers of immunogenicity against the anti-VEGF biotherapeutic brolucizumab. Sci Transl Med 2023;15. doi:10.1126\/scitranslmed.abq5068","DOI":"10.1126\/scitranslmed.abq5068"},{"key":"2026061105401315000_11.2.e002660.14","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/01.iae.0000226540.61840.d7","article-title":"Optical coherence tomography findings in hydroxychloroquine and chloroquine-associated maculopathy","volume":"1","author":"Fung","year":"2007","journal-title":"Retin Cases Brief Rep"},{"key":"2026061105401315000_11.2.e002660.15","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1007\/s40123-023-00735-8","article-title":"Potential for Treatment Interval Extension in Eyes with nAMD Disease Activity Post Loading Phase in HAWK and HARRIER","volume":"12","author":"Tadayoni","year":"2023","journal-title":"Ophthalmol Ther"},{"key":"2026061105401315000_11.2.e002660.16","first-page":"695","article-title":"Ocular Half-Life of Intravitreal Biologics in Humans and Other Species: Meta-Analysis and Model-Based Prediction","volume":"17","author":"Caruso","year":"2020","journal-title":"Mol Pharm"},{"key":"2026061105401315000_11.2.e002660.17","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.8b00280"},{"key":"2026061105401315000_11.2.e002660.18","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.7b00164"},{"key":"2026061105401315000_11.2.e002660.19","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.5b00849"}],"container-title":["BMJ Open Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjophth-2025-002660","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T12:40:21Z","timestamp":1781181621000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjophth.bmj.com\/lookup\/doi\/10.1136\/bmjophth-2025-002660"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,6,11]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/bmjophth-2025-002660"],"URL":"https:\/\/doi.org\/10.1136\/bmjophth-2025-002660","relation":{},"ISSN":["2397-3269"],"issn-type":[{"value":"2397-3269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}